Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · Indexed industry source record · Source published: Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertak
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.